Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells

Half, 2002, Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ, Cancer Res, 62, 1676 Ristimaki, 2002, Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer, Cancer Res, 62, 63263 Shim, 2003, Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium, Cancer Res, 63, 2347 Boland, 2004, COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ, Br J Cancer, 90, 423, 10.1038/sj.bjc.6601534 Davies, 2003, Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer, Clin Cancer Res, 9, 2651 Subbaramaiah, 1996, Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells, Cancer Res, 56, 4424 Denkert, 2003, Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma, Cancer, 97, 2978, 10.1002/cncr.11437 Bennett, 1977, Prostaglandins and breast cancer, Lancet, 2, 624, 10.1016/S0140-6736(77)92496-5 Rolland, 1980, Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells, J Natl Cancer Inst, 64, 1061 Witton, 2004, Cyclooxygenase 2 (COX-2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer, Histopathology, 45, 47, 10.1111/j.1365-2559.2004.01898.x Terry, 2004, Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk, JAMA, 291, 2433, 10.1001/jama.291.20.2433 Sun, 2002, Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells, Cancer Res, 62, 6323 Simeone, 2004, Cyclooxygenase-2 is essential for HER2/neu to suppress N-(4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells, Cancer Res, 64, 1224, 10.1158/0008-5472.CAN-03-2188 Mandlekar, 2001, Mechanisms of tamoxifen-induced apoptosis, Apoptosis, 6, 469, 10.1023/A:1012437607881 Zapata-Benavides, 2002, Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation, Biochem Biophys Res Commun, 295, 784, 10.1016/S0006-291X(02)00751-9 Pusztai, 2003, Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors, Clin Cancer Res, 9, 2406 Liu, 2001, Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice, J Biol Chem, 267, 18563, 10.1074/jbc.M010787200 Mizutani, 2002, Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer, J Urol, 168, 2650, 10.1016/S0022-5347(05)64237-1 Mangelsdorf, 1994, The retinoid receptors, 319 Sheikh, 1995, N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma, Carcinogenesis, 16, 2477, 10.1093/carcin/16.10.2477 Fanjul, 1996, 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors, J Biol Chem, 271, 22441, 10.1074/jbc.271.37.22441 Kazmi, 1996, Comparison of N-(4-hydroxyphenyl) retinamide and all-trans retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines, Cancer Res, 56, 1056 Dmitrovsky, 1997, N-(4-hydroxyphenyl)retinamide activation of a distinct pathway signaling apoptosis, J Natl Cancer Inst, 89, 1179, 10.1093/jnci/89.16.1179 Simeone, 2003, Her2/neu reduces the sensitivity of breast cancer cells to N-(4-hydroxyphenyl)retinamide, Oncogene, 22, 6739, 10.1038/sj.onc.1206786 Frasor, 2004, Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells, Cancer Res, 64, 1522, 10.1158/0008-5472.CAN-03-3326 Webb, 2003, Differential SERM effects on corepressor binding dictate ERalpha activity in vivo, J Biol Chem, 278, 6912, 10.1074/jbc.M208501200 Shang, 2002, Molecular determinants for the tissue specificity of SERMs, Science, 295, 2465, 10.1126/science.1068537 Brzozowski, 1997, Molecular basis of agonism and antagonism in the oestrogen receptor, Nature, 389, 753, 10.1038/39645 Shiau, 1998, The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen, Cell, 95, 927, 10.1016/S0092-8674(00)81717-1 Chang, 2004, Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression, Proc Natl Acad Sci USA, 101, 591, 10.1073/pnas.2535911100 Timoshenko, 2003, Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells, Exp Cell Res, 289, 265, 10.1016/S0014-4827(03)00269-6 Tonetti, 2000, Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines, Br J Cancer, 83, 782, 10.1054/bjoc.2000.1326 Tonetti, 2003, Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure, Br J Cancer, 88, 1400, 10.1038/sj.bjc.6600923 Fujimoto, 1994, Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence, Mol Endocrinol, 8, 296 Michalides, 2004, Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer, Cancer Cell, 5, 597, 10.1016/j.ccr.2004.05.016 Miller, 1990, Cyclic AMP binding proteins and prognosis in breast cancer, Br J Cancer, 61, 263, 10.1038/bjc.1990.48 Miller, 1993, Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer, Breast Cancer Res Treat, 26, 89, 10.1007/BF00682703 Howe, 2002, Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer, Cancer Res, 62, 5405 Kawamori, 2001, Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development, Carcinogenesis, 22, 2001, 10.1093/carcin/22.12.2001